Home/Hedge Fund Intelligence/Ascendis Pharma A/S
Nasdaq: ASNDStockForm 13F30 Jun 2026

Hedge funds that hold Ascendis Pharma A/S Shs Nasdaq: ASND

Shs · CUSIP K08588103 · who reports it, how much, and how much it matters to them

36 of the 720 hedge fund managers we track reported shares of Ascendis Pharma A/S (Nasdaq: ASND) on Form 13F for 30 June 2026. Between them they reported USD 5.9bn. The largest position belongs to Ra Capital Management, at USD 2.7bn.

Managers reporting it36of 720 we track
Value they reportUSD 5.9bnshares only, 30 Jun 2026
Funds they run553with a file on PPLI.com
Largest positionUSD 2.7bnRa Capital Management
Typical weight0.1%median share of a manager's book
Heaviest weight23.8%Ra Capital Management

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

36 managers, USD 5.9bn between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Ascendis Pharma A/S, largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Ra Capital Management1 fund on PPLI.comUSD 2.7bn23.8%
2Avoro Capital Advisors1 fund on PPLI.comUSD 1.4bn12.2%
3Artisan Partners1 fund on PPLI.comUSD 703m1.1%
4Perceptive Advisors6 funds on PPLI.comUSD 310m4.7%
5Polar Capital LLP26 funds on PPLI.comUSD 165m0.4%
6Two Sigma Investments35 funds on PPLI.comUSD 82m0.1%
7Millennium Management6 funds on PPLI.comUSD 71m0.0%
8Orbimed Advisors1 fund on PPLI.comUSD 65m1.2%
9PFM Health Sciences3 funds on PPLI.comUSD 62m5.3%
10Rock Springs Capital Management2 funds on PPLI.comUSD 45m2.2%
11Citadel Advisors32 funds on PPLI.comUSD 37m0.0%
12Walleye Capital8 funds on PPLI.comUSD 34m0.1%
13Renaissance Technologies13 funds on PPLI.comUSD 32m0.0%
14Resolute Capital Asset Partners1 fund on PPLI.comUSD 32m13.5%
15Eagle Health Investments1 fund on PPLI.comUSD 28m4.7%
16Adage Capital Management1 fund on PPLI.comUSD 18m0.0%
17Atika Capital Management3 funds on PPLI.comUSD 16m1.1%
18Cormorant Asset Management1 fund on PPLI.comUSD 13m0.7%
19Dafna Capital Management6 funds on PPLI.comUSD 13m2.5%
20Eversept Partners3 funds on PPLI.comUSD 11m0.6%
21Balyasny Asset Management25 funds on PPLI.comUSD 8.3m0.0%
22D. E. Shaw & Co.15 funds on PPLI.comUSD 8.2m0.0%
23Voloridge Investment Management6 funds on PPLI.comUSD 7.8m0.0%
24Marshall Wace LLP84 funds on PPLI.comUSD 6m0.0%
25Artia Global Partners1 fund on PPLI.comUSD 4.7m0.9%
26Tudor Investment Corporation10 funds on PPLI.comUSD 4.4m0.0%
27Lighthouse Investment Partners190 funds on PPLI.comUSD 3.2m0.1%
28Squarepoint Ops7 funds on PPLI.comUSD 2.6m0.0%
29Engineers Gate Manager1 fund on PPLI.comUSD 2.6m0.0%
30Brevan Howard Capital Management39 funds on PPLI.comUSD 2.1m0.0%
31Atom Investors1 fund on PPLI.comUSD 2.1m0.2%
32Exome Asset Management2 funds on PPLI.comUSD 1.8m1.1%
33Campbell & Company Investment Adviser8 funds on PPLI.comUSD 1.7m0.1%
34Persistent Asset Partners10 funds on PPLI.comUSD 87,2170.0%
35The Quarry1 fund on PPLI.comUSD 1,6000.0%
36Elequin Capital2 funds on PPLI.comUSD 1,0670.0%
Next: where it matters most
Where it matters most

For Ra Capital Management it is 23.8% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1Ra Capital ManagementUSD 2.7bn23.8%
2Resolute Capital Asset PartnersUSD 32m13.5%
3Avoro Capital AdvisorsUSD 1.4bn12.2%
4PFM Health SciencesUSD 62m5.3%
5Eagle Health InvestmentsUSD 28m4.7%
6Perceptive AdvisorsUSD 310m4.7%
7Dafna Capital ManagementUSD 13m2.5%
8Rock Springs Capital ManagementUSD 45m2.2%
9Orbimed AdvisorsUSD 65m1.2%
10Artisan PartnersUSD 703m1.1%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Ascendis Pharma A/S

What is the ticker symbol of Ascendis Pharma A/S?

Ascendis Pharma A/S trades under the symbol ASND on the Nasdaq. Its CUSIP, the code used on Form 13F, is K08588103.

Which hedge funds own Ascendis Pharma A/S (Nasdaq: ASND)?

36 of the 720 hedge fund managers PPLI.com tracks reported Ascendis Pharma A/S shares on Form 13F for 30 June 2026. The largest reported positions were held by Ra Capital Management (USD 2.7bn), Avoro Capital Advisors (USD 1.4bn), Artisan Partners (USD 703m), Perceptive Advisors (USD 310m) and Polar Capital LLP (USD 165m).

How many hedge funds hold Ascendis Pharma A/S?

36 managers in our coverage reported it, and between them they run 553 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Ascendis Pharma A/S?

Ra Capital Management, where the position was 23.8% of the reported 13F book at 30 June 2026.

Does this show who is short Ascendis Pharma A/S?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Ascendis Pharma A/S or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.